Is GLOW approved anywhere?

No. None of its three components holds a marketing authorisation, and neither does the blend.

Does BPC-157's Phase 2 trial change that?

No. A recruiting trial is a question being asked. Primary completion is February 2027, and a trial is not an approval.

Why is a blend a higher claims risk?

It invites language about components working together, and no published work addresses this combination at all.

GLOW (Blend)

GLOW Regulatory Status

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

None of GHK-Cu, BPC-157 or TB-500 holds a marketing authorisation from the MHRA, EMA or FDA, and neither does the blend. Combining unlicensed compounds does not create a licensed product.

Key facts

GHK-Cu: Not authorised as a medicine
BPC-157: Not authorised
TB-500: Not authorised
The blend: Not authorised
BPC-157 trials: Phase 2 recruiting — not approval
Supply basis here: Laboratory research only

The position

No regulator has assessed any of the three components as a medicine, and no regulator has assessed the blend. There is no marketing authorisation, no indication, no label. It is supplied for laboratory research only.

What a trial in progress does not mean

BPC-157 has a recruiting Phase 2 trial, NCT07437547, which is more clinical activity than most compounds in this catalogue have. A trial in progress is a question being asked, not an answer, and certainly not an approval. Primary completion is February 2027 and publication would follow.

Research material referenced

GLOW 70mg — third-party HPLC tested

View — £59.99

The claim risk specific to a blend

A blend invites language a single compound does not — that components work together, complement each other, or produce a combined effect. Each of those is a claim about the combination, and no published work addresses this combination at all. The format makes overstatement easier while providing less evidence to support it.

The category name is claim-adjacent

Skin and anti-ageing is how the product is filed commercially. Anti-ageing is close to a claim before anything else is said, and the articles in this category deliberately confine themselves to component chemistry, blend format and research literature rather than any statement about skin or appearance.

What is said here

Component identities and masses, the chemistry of co-lyophilising a copper complex with cysteine-free and methionine-free peptides, the trade-offs of a fixed-ratio format, and what a blend certificate can and cannot establish. Not said: that this product does anything to anyone's skin, appearance or ageing.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic and cosmetic claims about unregulated peptide products in April 2026. The framework turns on the claim and the intended use, and applies to a blend exactly as it applies to a single compound.

Extended research context

The GLOW (Blend) deep dive

Deep dive: the copper question, and why this particular set of partners answers it

Copper is redox-active and catalyses oxidation. In protein chemistry this is well established - trace copper accelerates thiol oxidation, disulfide scrambling and methionine oxidation, which is why chelating agents appear in so many formulation buffers. So putting a copper complex in a vial with two other peptides is a fair thing to interrogate rather than wave through. Copper attacks two residues in particular: cysteine, whose free thiol is the most readily oxidised side chain in the standard set, and methionine, whose thioether becomes the sulfoxide at plus 16 daltons. Now look at what is actually in the vial. BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val - no cysteine, no methionine. TB-500 is an acetylated seven-residue fragment with the same absence. The reaction copper would catalyse has no substrate present. That is a real finding rather than a reassurance, because it would not have held for many other combinations: glutathione is defined by a free thiol that oxidises in air with no catalyst at all, and IGF-1 LR3 carries three disulfide bonds whose correct pairing copper would actively disrupt. Neither belongs in a vial with GHK-Cu. This set does.

Deep dive: a blend takes the fixed ratio without the single profile

There are three ways to combine compounds and they are genuinely different propositions. Separate vials, each used independently. A blend, combined at manufacture. Or one molecule engineered to hit several targets, as retatrutide does across three receptors. The real advantage of the third is not that it hits several targets - it is that it has ONE pharmacokinetic profile. Retatrutide's three activities cannot fall out of step with each other because absorption, distribution and clearance apply to all three at once, and that is why the field pursues multi-agonism despite how hard the chemistry is. A blend buys none of that. Three peptides in one vial remain three peptides with three masses, three solubilities, three stabilities and three clearance behaviours; combining them changes the packaging, not the pharmacology. What it does cost is the ratio, which is fixed at manufacture - reconstituting in a different volume moves all three concentrations together and never their relationship. So a blend carries the inflexibility of a multi-agonist without the simplification that justifies it. What it offers instead is convenience: fewer vials, fewer reconstitutions, fewer transfers, less material lost to surfaces at each step. That is a real benefit and it is a practical one, not a pharmacological one.

Deep dive: why a blend cannot answer the question it invites

Blends invite the word synergy, so it is worth being precise about what that word means. Not that a combination works - that a combination produces MORE than its components produce independently. Two compounds each giving one unit of effect, combined giving two, is additive and entirely unremarkable. Three units would be synergy. Demonstrating it requires each component alone at the concentration present in the combination, the combination itself, and matched conditions throughout; without the individual arms there is no baseline to exceed, so a combination result on its own can never establish synergy however large it is. Here is the structural problem: those individual arms need the components separately at known concentrations, and a fixed-ratio blend whose per-component split is not stated supplies neither. The experiment that would test the claim cannot be designed from the product that prompts it. The honest position is not that synergy has been ruled out for this combination - it is that no published work addresses this combination at all, which is a different and more accurate statement. The rationale for putting these three together is overlapping research literatures in collagen, repair and cell migration, and that is a reasonable basis for a product without being evidence that the compounds interact.

Research applications

▸Combined connective tissue and matrix research protocols
▸Collagen synthesis and remodelling model systems
▸Comparative work on single compounds versus fixed combinations
▸Copper peptide coordination chemistry
▸Co-lyophilisation and multi-component formulation methodology
▸Cell migration and wound model research

Handling checklist

✓Verify GHK-Cu against 402.92 Da (CID 71587328), not 340.38 - that is free GHK
✓Verify BPC-157 against 1419.5 Da and TB-500 against 889.0 Da, not 4.9 kDa
✓Expect per-component certification - a single purity figure for a blend is a category error
✓Note the per-component mass split is not stated; no molar calculation is possible without it
✓Store lyophilised, cold, dry and protected from light - the copper complex governs
✓Reconstitute gently down the vial wall; uneven dissolution is expected and needs time, not shaking
✓Expect no disulfide or +16 Da oxidation species - no component carries cysteine or methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Quoting 340.38 Da for the GHK-Cu component

Fix: That is free GHK without copper, CID 73587. The complex is 402.92 Da, CID 71587328 - a 15% difference.

✗ Quoting 4.9 kDa for the TB-500 component

Fix: That is full thymosin beta-4, the 43-residue parent protein. TB-500 is a seven-residue fragment at 889.0 Da - a 5.6-fold error.

✗ Expecting a single purity figure for the blend

Fix: With three intended compounds the other two are neither impurities nor the analyte. Each component must be verified separately before blending.

✗ Shaking to help an unevenly dissolving cake

Fix: Components of different size and solubility dissolve at different rates. Shaking creates interfaces where peptides aggregate irreversibly. Swirl and wait.

✗ Reading a blend as evidence the components act together

Fix: No published work addresses this combination. The rationale is overlapping research areas, which is not evidence of interaction.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is GLOW approved anywhere?: No. None of its three components holds a marketing authorisation, and neither does the blend.
Does BPC-157's Phase 2 trial change that?: No. A recruiting trial is a question being asked. Primary completion is February 2027, and a trial is not an approval.
Why is a blend a higher claims risk?: It invites language about components working together, and no published work addresses this combination at all.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLOW (Blend) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum